SCHEMBL11890885

SCHEMBL11890885

CC(C)(C)C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO

nearest known ligand 0.58

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
TDP1 Q9NUW8 2/20 0.55
KDM4E B2RXH2 2/20 0.46
PDE4A P27815 1/20 0.41
USP2 O75604 1/20 0.38
SLCO1B1 Q9Y6L6 1/20 0.38
ALDH1A1 P00352 1/20 0.35
TOP1 P11387 1/20 0.33
MAPT P10636 1/20 0.31
MGAM O43451 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11890936 1.00 LMNA (0.58) LMNAL3MBTL1TDP1KDM4EPDE4A
SCHEMBL15802525 1.00 LMNA (0.58) LMNAL3MBTL1TDP1KDM4EPDE4A
SCHEMBL11890865 1.00 LMNA (0.58) LMNAL3MBTL1TDP1KDM4EPDE4A
SCHEMBL11890883 1.00 LMNA (0.58) LMNAL3MBTL1TDP1KDM4EPDE4A
SCHEMBL11890869 1.00 LMNA (0.58) LMNAL3MBTL1TDP1KDM4EPDE4A
SCHEMBL11890894 1.00 LMNA (0.58) LMNAL3MBTL1TDP1KDM4EPDE4A
SCHEMBL11890864 1.00 LMNA (0.58) LMNAL3MBTL1TDP1KDM4EPDE4A
SCHEMBL11890853 1.00 LMNA (0.58) LMNAL3MBTL1TDP1KDM4EPDE4A
SCHEMBL11890855 1.00 LMNA (0.58) LMNAL3MBTL1TDP1KDM4EPDE4A
SCHEMBL11890870 1.00 LMNA (0.58) LMNAL3MBTL1TDP1KDM4EPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120190832-A1 LOW-MOLECULAR SERINE PROTEASES INHIBITORS COMPRISING POLYHYDROXY-ALKYL AND POLYHYDROXY-CYCLOALKYL RADICALS ABBOTT GMBH & CO. KG (DE) 2012-07-26 US disclosed
US-20120190832-A1 LOW-MOLECULAR SERINE PROTEASES INHIBITORS COMPRISING POLYHYDROXY-ALKYL AND POLYHYDROXY-CYCLOALKYL RADICALS ABBOTT GMBH & CO. KG (DE) 2012-07-26 US disclosed
US-20110071285-A1 LOW-MOLECULAR SERINE PROTEASES INHIBITORS COMPRISING POLYHYDROXY-ALKYL AND POLYHYDROXY-CYCLOALKYL RADICALS ABBOTT GMBH & CO. KG (DE) 2011-03-24 US disclosed
US-20110071285-A1 LOW-MOLECULAR SERINE PROTEASES INHIBITORS COMPRISING POLYHYDROXY-ALKYL AND POLYHYDROXY-CYCLOALKYL RADICALS ABBOTT GMBH & CO. KG (DE) 2011-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071285-A1 LOW-MOLECULAR SERINE PROTEASES INHIBITORS COMPRISING POLYHYDROXY-ALKYL AND POLYHYDROXY-CYCLOALKYL RADICALS F2R, C1R, PRSS1 LMNA 1975/4885L3MBTL1 3434/4885TDP1 1556/4885
US-20120190832-A1 LOW-MOLECULAR SERINE PROTEASES INHIBITORS COMPRISING POLYHYDROXY-ALKYL AND POLYHYDROXY-CYCLOALKYL RADICALS F2R, C1R, PRSS1 LMNA 1975/4885L3MBTL1 3434/4885TDP1 1556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.